organization · Reporting owner
Boxer Capital Management, LLC
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tango Therapeutics, Inc.
Report date November 06, 2024 · Filed November 08, 2024
Jointly reported with Davis Aaron I.
Section 16 reporting ended · disclosed 2024-11-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,610,642 |
Reported balance
After 2024-11-06 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2024-11-06 · Sale · Disposed 3,080,000 · Balance 3,610,642 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0000 to $3.3955, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These securities are held indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of an account holding such securities. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Mr. Davis is the Managing Member of BCM and has voting and dispositive power over securities beneficially owned by BCM, but disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 108,793 |
Reported balance
Holding disclosure · report date 2024-11-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 108,793 F3: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors, but disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. BCM disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 6,988,450 |
Reported balance
Holding disclosure · report date 2024-11-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,988,450 F4: These securities are owned directly by BCTG Holdings, LLC ("BCTG"). MVA Investors is a member of BCTG. Mr. Davis is a member of the investment committee of BCTG. Mr. Davis disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any. BCM disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0000 to $3.3955, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: These securities are held indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of an account holding such securities. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Mr. Davis is the Managing Member of BCM and has voting and dispositive power over securities beneficially owned by BCM, but disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, if any.
F3: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors, but disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. BCM disclaims beneficial ownership of these securities.
F4: These securities are owned directly by BCTG Holdings, LLC ("BCTG"). MVA Investors is a member of BCTG. Mr. Davis is a member of the investment committee of BCTG. Mr. Davis disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any. BCM disclaims beneficial ownership of these securities.
Tyra Biosciences, Inc.
Report date October 18, 2024 · Filed October 23, 2024
Section 16 reporting ended · disclosed 2024-10-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,448,359 |
Reported balance
After 2024-10-18 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-10-18 · Disposition to issuer · Disposed 2,000,000 · Balance 4,448,359 F1: On October 18, 2024, Boxer Capital, LLC ("Boxer") entered into an exchange agreement with the Issuer, pursuant to which Boxer agreed to exchange 2,000,000 shares of the Issuer's Common Stock for a pre-funded warrant to purchase up to 2,000,000 shares of Common Stock (the "Pre-Funded Warrant"). The Pre-Funded Warrant was issued on October 22, 2024. F2: These securities are beneficially owned indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of Boxer. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Pre-Funded Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | 2,705,280 |
Reported balance
After 2024-10-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-10-18 · Grant · Acquired 2,000,000 · Balance 2,705,280 F1: On October 18, 2024, Boxer Capital, LLC ("Boxer") entered into an exchange agreement with the Issuer, pursuant to which Boxer agreed to exchange 2,000,000 shares of the Issuer's Common Stock for a pre-funded warrant to purchase up to 2,000,000 shares of Common Stock (the "Pre-Funded Warrant"). The Pre-Funded Warrant was issued on October 22, 2024. F3: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. A holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2: These securities are beneficially owned indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of Boxer. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 18, 2024, Boxer Capital, LLC ("Boxer") entered into an exchange agreement with the Issuer, pursuant to which Boxer agreed to exchange 2,000,000 shares of the Issuer's Common Stock for a pre-funded warrant to purchase up to 2,000,000 shares of Common Stock (the "Pre-Funded Warrant"). The Pre-Funded Warrant was issued on October 22, 2024.
F2: These securities are beneficially owned indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of Boxer. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F3: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. A holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 06, 2024 Filed Nov 8, 2024 02:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | SaleCommon Stock | 3,080,000 | $3.14 | $9,671,200.00 |
DisclosureSEC source: 0000895345-24-000548 · form4.xml · nonDerivative · entry 1 Boxer Capital Management, LLC · CIK 0002018299 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,610,642 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0000 to $3.3955, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of an account holding such securities. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Mr. Davis is the Managing Member of BCM and has voting and dispositive power over securities beneficially owned by BCM, but disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, if any. Read SEC document |
| October 25, 2024 Filed Oct 28, 2024 10:59 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | SaleCommon Stock | 633,000 | $6.87 | $4,348,710.00 |
DisclosureSEC source: 0000895345-24-000485 · form4.xml · nonDerivative · entry 1 Boxer Capital Management, LLC · CIK 0002018299 · See remarks. Davis Aaron I. · CIK 0001465914 · See remarks. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,690,642 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.8500 to $6.8700, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: These securities are held indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of an account holding such securities. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Mr. Davis is the Managing Member of BCM and has voting and dispositive power over securities beneficially owned by BCM, but disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, if any. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 01:31 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | SaleCommon Stock | 250,000 | $6.78 | $1,695,000.00 |
DisclosureSEC source: 0000895345-24-000470 · form4.xml · nonDerivative · entry 2 Boxer Capital Management, LLC · CIK 0002018299 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,323,642 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.7100 to $6.9050, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: These securities are held indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of an account holding such securities. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Mr. Davis is the Managing Member of BCM and has voting and dispositive power over securities beneficially owned by BCM, but disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, if any. Read SEC document |
| October 21, 2024 Filed Oct 24, 2024 01:31 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | SaleCommon Stock | 625,000 | $7.05 | $4,406,250.00 |
DisclosureSEC source: 0000895345-24-000470 · form4.xml · nonDerivative · entry 1 Boxer Capital Management, LLC · CIK 0002018299 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,573,642 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0018 to $7.2372, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: These securities are held indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of an account holding such securities. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Mr. Davis is the Managing Member of BCM and has voting and dispositive power over securities beneficially owned by BCM, but disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, if any. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 00:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantPre-Funded Warrant (right to purchase) · Derivative | 2,000,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000895345-24-000458 · form4.xml · derivative · entry 2 Boxer Capital Management, LLC · CIK 0002018299 · See remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,705,280 Underlying: Common Stock · 2,000,000 shares Expires not disclosed F1 · kind: On October 18, 2024, Boxer Capital, LLC ("Boxer") entered into an exchange agreement with the Issuer, pursuant to which Boxer agreed to exchange 2,000,000 shares of the Issuer's Common Stock for a pre-funded warrant to purchase up to 2,000,000 shares of Common Stock (the "Pre-Funded Warrant"). The Pre-Funded Warrant was issued on October 22, 2024. F1 · price: On October 18, 2024, Boxer Capital, LLC ("Boxer") entered into an exchange agreement with the Issuer, pursuant to which Boxer agreed to exchange 2,000,000 shares of the Issuer's Common Stock for a pre-funded warrant to purchase up to 2,000,000 shares of Common Stock (the "Pre-Funded Warrant"). The Pre-Funded Warrant was issued on October 22, 2024. F3 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. A holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. A holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: These securities are beneficially owned indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of Boxer. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 00:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Disposition to issuerCommon Stock | 2,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-24-000458 · form4.xml · nonDerivative · entry 1 Boxer Capital Management, LLC · CIK 0002018299 · See remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,448,359 F1 · kind: On October 18, 2024, Boxer Capital, LLC ("Boxer") entered into an exchange agreement with the Issuer, pursuant to which Boxer agreed to exchange 2,000,000 shares of the Issuer's Common Stock for a pre-funded warrant to purchase up to 2,000,000 shares of Common Stock (the "Pre-Funded Warrant"). The Pre-Funded Warrant was issued on October 22, 2024. F1 · price: On October 18, 2024, Boxer Capital, LLC ("Boxer") entered into an exchange agreement with the Issuer, pursuant to which Boxer agreed to exchange 2,000,000 shares of the Issuer's Common Stock for a pre-funded warrant to purchase up to 2,000,000 shares of Common Stock (the "Pre-Funded Warrant"). The Pre-Funded Warrant was issued on October 22, 2024. F2 · ownership.nature: These securities are beneficially owned indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of Boxer. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.